Cargando…
Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
OBJECTIVE: This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks. METHODS: In this phase 3b, randomized, open‐label, controlled study, subjects received...
Autores principales: | Halseth, Amy, Shan, Kevin, Walsh, Brandon, Gilder, Kye, Fujioka, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299461/ https://www.ncbi.nlm.nih.gov/pubmed/28026920 http://dx.doi.org/10.1002/oby.21726 |
Ejemplares similares
-
Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012) -
Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018) -
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013) -
Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016) -
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)